FR2322601A1
(fr)
*
|
1975-09-04 |
1977-04-01 |
Rhone Poulenc Ind |
Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
|
AR208414A1
(es)
*
|
1974-11-07 |
1976-12-27 |
Rhone Poulenc Ind |
Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
|
JPS5680585A
(en)
*
|
1979-11-30 |
1981-07-01 |
Toyoda Gosei Kk |
High pressure hose
|
JPS57144860A
(en)
*
|
1981-03-04 |
1982-09-07 |
Matsushita Electric Ind Co Ltd |
Secondary side water pressure controller for water cooler
|
JPS6169773A
(ja)
*
|
1984-09-14 |
1986-04-10 |
Takeda Chem Ind Ltd |
イソインドリノン誘導体
|
JPS6297400U
(pt)
*
|
1985-12-09 |
1987-06-20 |
|
|
FR2607504B1
(fr)
*
|
1986-12-02 |
1989-01-27 |
Rhone Poulenc Sante |
Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2671800B1
(fr)
*
|
1991-01-17 |
1993-03-12 |
Rhone Poulenc Rorer Sa |
Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
|
WO1993010788A1
(en)
*
|
1991-12-02 |
1993-06-10 |
Sepracor, Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
|
WO1993010787A1
(en)
*
|
1991-12-02 |
1993-06-10 |
Sepracor, Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
|
US5786357A
(en)
|
1991-12-02 |
1998-07-28 |
Sepracor Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
|
EP1100508B8
(en)
|
1998-06-09 |
2004-01-07 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
|
US6339086B1
(en)
*
|
1999-05-14 |
2002-01-15 |
Swpracor, Inc. |
Methods of making and using N-desmethylzopiclone
|
ES2203319B1
(es)
*
|
2002-04-03 |
2005-03-01 |
Universidad De Oviedo |
Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
|
PT1691811E
(pt)
|
2003-12-11 |
2014-10-30 |
Sunovion Pharmaceuticals Inc |
Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
|
MX2008000250A
(es)
|
2005-07-06 |
2008-03-19 |
Sepracor Inc |
Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
|
WO2007005961A2
(en)
*
|
2005-07-06 |
2007-01-11 |
Sepracor Inc. |
Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
US7476737B2
(en)
*
|
2005-09-05 |
2009-01-13 |
Dr. Reddy's Laboratories Limited |
Eszopiclone process
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
US20070112017A1
(en)
*
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
EP1984371A1
(en)
*
|
2006-02-03 |
2008-10-29 |
Synthon B.V. |
Zopiclone resolution using l-tartaric acid
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
EP1991212A1
(en)
*
|
2006-03-08 |
2008-11-19 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20080027223A1
(en)
*
|
2006-03-23 |
2008-01-31 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
EP2007768A2
(en)
*
|
2006-04-20 |
2008-12-31 |
Teva Pharmaceutical Industries Ltd |
Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
|
CN101058581B
(zh)
*
|
2006-04-21 |
2011-06-08 |
天津天士力集团有限公司 |
右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
|
MX2008014320A
(es)
*
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US20080015197A1
(en)
*
|
2006-06-26 |
2008-01-17 |
Alex Mainfeld |
Process for the preparatrion of zopiclone
|
EP2068872A1
(en)
*
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
EP2066355A2
(en)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
US7786304B2
(en)
*
|
2006-11-06 |
2010-08-31 |
Centaur Pharmaceutical Pvt. Ltd. |
Process for the preparation of eszopiclone
|
TW200846340A
(en)
*
|
2007-01-31 |
2008-12-01 |
Teva Pharma |
Methods for preparing eszopiclone
|
US20080305171A1
(en)
*
|
2007-06-07 |
2008-12-11 |
Kristin Anne Arnold |
Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
|
WO2009002552A1
(en)
*
|
2007-06-25 |
2008-12-31 |
Teva Pharmaceutical Industries Ltd. |
Racemization process of r-zopiclone
|
EP2020403A1
(en)
|
2007-08-02 |
2009-02-04 |
Esteve Quimica, S.A. |
Process for the resolution of zopiclone and intermediate compounds
|
WO2009063486A2
(en)
*
|
2007-08-06 |
2009-05-22 |
Usv Limited |
Process for preparation of dextrorotatory isomer of 6-(5-chloro-pyrid-2-yi)-5-[(4-methyl -1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo [3,4-b] pyrazine (eszopiclone)
|
JP2011506427A
(ja)
*
|
2007-12-11 |
2011-03-03 |
シプラ・リミテッド |
ゾピクロンおよびその多形相の新規製造方法
|
US8198277B2
(en)
|
2007-12-19 |
2012-06-12 |
Sunovion Pharmaceuticals Inc. |
L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
WO2009085988A1
(en)
*
|
2007-12-19 |
2009-07-09 |
Sepracor Inc. |
Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7- dihydro-5h-pyrrolo[3,4-b]pyrazine
|
CN100467471C
(zh)
*
|
2007-12-19 |
2009-03-11 |
齐鲁天和惠世制药有限公司 |
佐匹克隆的制备方法
|
US8212036B2
(en)
*
|
2007-12-19 |
2012-07-03 |
Sunovion Pharmaceuticals Inc. |
Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8268832B2
(en)
*
|
2007-12-19 |
2012-09-18 |
Sunovion Pharmaceuticals Inc. |
Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8269005B2
(en)
*
|
2007-12-19 |
2012-09-18 |
Sunovion Pharmaceuticals Inc. |
L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
WO2009085972A1
(en)
*
|
2007-12-19 |
2009-07-09 |
Sepracor Inc. |
Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
|
US8198278B2
(en)
*
|
2007-12-19 |
2012-06-12 |
Sunovion Pharmaceuticals Inc. |
Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
AU2010208240A1
(en)
|
2009-01-30 |
2011-09-22 |
Sunovion Pharmaceuticals Inc |
Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5H-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
CN105399745A
(zh)
*
|
2015-12-17 |
2016-03-16 |
天津华津制药有限公司 |
一种吡嗪并羟基吡咯烷酮类化合物的制备方法
|
US11547706B2
(en)
|
2016-06-08 |
2023-01-10 |
President And Fellows Of Harvard College |
Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome
|
CN106220630B
(zh)
*
|
2016-07-23 |
2019-12-10 |
迪嘉药业集团有限公司 |
一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
|
AU2019279858A1
(en)
*
|
2018-05-29 |
2020-11-26 |
President And Fellows Of Harvard College |
Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
|